Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Esjay Pharma

Pharmaceutical intelligence for Esjay Pharma with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
0
Assets
2

Recent signals(2)

RegulatoryAugust 1, 2026

FDA Grants Approval for Glycerol Phenylbutyrate by Esjay Pharma

The FDA has granted approval for the ANDA220579 application for Glycerol Phenylbutyrate submitted by Esjay Pharma.

RegulatoryJuly 9, 2026

FDA Accepts Supplement for PARLODEL by Esjay Pharma

The FDA has accepted a supplemental application for PARLODEL (bromocriptine mesylate) from Esjay Pharma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(2)

RegulatoryAugust 1, 2026

FDA Grants Approval for Glycerol Phenylbutyrate by Esjay Pharma

The FDA has granted approval for the ANDA220579 application for Glycerol Phenylbutyrate submitted by Esjay Pharma.

RegulatoryJuly 9, 2026

FDA Accepts Supplement for PARLODEL by Esjay Pharma

The FDA has accepted a supplemental application for PARLODEL (bromocriptine mesylate) from Esjay Pharma.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

FDA →
PARLODEL →

Therapeutic areas

Dopamine Agonist →
Endocrinology →
Metabolic Disorders →
Urea Cycle Disorders →

Indications

Metabolic Disorders →
Urea Cycle Disorders →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.